Contrasting Klotho Neurosciences (KLTO) and Its Rivals

Profitability

This table compares Klotho Neurosciences and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	-1,779.01%	-275.01%
Klotho Neurosciences Competitors	-19,902.74%	-91.90%	-26.01%

Insider and Institutional Ownership

20.1% of Klotho Neurosciences shares are held by institutional investors. Comparatively, 44.0% of shares of all “MED – DRUGS” companies are held by institutional investors. 26.7% of Klotho Neurosciences shares are held by insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Klotho Neurosciences and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Klotho Neurosciences	N/A	-$6.15 million	-4.28
Klotho Neurosciences Competitors	$1.08 billion	$58.11 million	-6.03

Klotho Neurosciences’ competitors have higher revenue and earnings than Klotho Neurosciences. Klotho Neurosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Klotho Neurosciences has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Klotho Neurosciences’ competitors have a beta of 0.53, meaning that their average stock price is 47% less volatile than the S&P 500.

Summary

Klotho Neurosciences competitors beat Klotho Neurosciences on 6 of the 9 factors compared.

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.